Israel
· Delayed Price · Currency is ILS · Price in ILACan-Fite BioPharma Statistics
Total Valuation
Can-Fite BioPharma has a market cap or net worth of ILS 63.37 million. The enterprise value is 45.78 million.
| Market Cap | 63.37M |
| Enterprise Value | 45.78M |
Important Dates
The next estimated earnings date is Thursday, November 28, 2024.
| Earnings Date | Nov 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Can-Fite BioPharma has 2.04 billion shares outstanding. The number of shares has increased by 57.39% in one year.
| Shares Outstanding | 2.04B |
| Shares Change (YoY) | +57.39% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 5.01% |
| Float | 2.04B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.60 |
| PB Ratio | 5.56 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.65 |
| EV / Sales | 18.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.64 |
Financial Position
The company has a current ratio of 2.93, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.93 |
| Quick Ratio | 2.38 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -157.62% and return on invested capital (ROIC) is -102.80%.
| Return on Equity (ROE) | -157.62% |
| Return on Assets (ROA) | -57.46% |
| Return on Capital (ROIC) | -102.80% |
| Revenue Per Employee | 313,915 |
| Profits Per Employee | -3.47M |
| Employee Count | 8 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.45% in the last 52 weeks. The beta is 0.61, so Can-Fite BioPharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -6.45% |
| 50-Day Moving Average | 3.02 |
| 200-Day Moving Average | 2.92 |
| Relative Strength Index (RSI) | 53.70 |
| Average Volume (20 Days) | 15,462,403 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of ILS 2.51 million and -27.75 million in losses. Loss per share was -0.02.
| Revenue | 2.51M |
| Gross Profit | 2.51M |
| Operating Income | -29.34M |
| Pretax Income | -27.75M |
| Net Income | -27.75M |
| EBITDA | -29.31M |
| EBIT | -29.34M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 17.80 million in cash and 214,611 in debt, giving a net cash position of 17.59 million or 0.01 per share.
| Cash & Cash Equivalents | 17.80M |
| Total Debt | 214,611 |
| Net Cash | 17.59M |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 9.33M |
| Book Value Per Share | 0.01 |
| Working Capital | 14.46M |
Cash Flow
In the last 12 months, operating cash flow was -27.98 million and capital expenditures -15,060, giving a free cash flow of -27.99 million.
| Operating Cash Flow | -27.98M |
| Capital Expenditures | -15,060 |
| Free Cash Flow | -27.99M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,168.37% |
| Pretax Margin | -1,105.10% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,114.69% |
Dividends & Yields
Can-Fite BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -57.39% |
| Shareholder Yield | -57.39% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
The last stock split was on May 12, 2013. It was a reverse split with a ratio of 0.04.
| Last Split Date | May 12, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
Can-Fite BioPharma has an Altman Z-Score of -40.01. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -40.01 |
| Piotroski F-Score | n/a |